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Congenital emphysematous lung disease
associated with a novel Filamin A mutation.
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Abstract
Background: Progressive lung involvement in Filamin A (FLNA)-related cerebral periventricular nodular heterotopia
(PVNH) has been reported in a limited number of cases.
Case presentation: We report a new pathogenic FLNA gene variant (c.7391_7403del; p.Val2464Alafs*5) in a male
infant who developed progressive lung disease with emphysematous lesions and interstitial involvement. Following
lobar resection, chronic respiratory failure ensued necessitating continuous mechanical ventilation and tracheostomy.
Cerebral periventricular nodular heterotopia was also present.
Conclusions: We report a novel variant of the FLNA gene, associated with a severe lung disorder and PNVH. The lung
disorder led to respiratory failure during infancy and these pulmonary complications may be the first sign of this
disorder. Early recognition with thoracic imaging is important to guide genetic testing, neuroimaging and to define
optimal timing of potential therapies, such as lung transplant in progressive lung disease.
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Background
Filamins are large actin-binding proteins that stabilize deli-
cate three-dimensional actin webs and link these to cellular
membranes. They integrate cellular architectural and sig-
nalling functions and are essential for fetal development
and cell locomotion [1].
Filamin A (FLNA) is the first actin filament cross-linking
protein identified in non-muscle cells. Mutations in the
X-linked gene encoding filamin A (at chromosomal locus
Xq28) have been reported to cause a wide range of human
diseases, such as cerebral periventricular nodular heteroto-
pia (PVNH), cardiac valvular disease and skeletal anomalies
to a variable degree [2–10]. Airway anomalies such as
tracheal stenosis or tracheobronchomalacia have also been
documented and recently lung involvement has been
reported [2, 11–22].
FLNA-related PVNH is a malformation of cortical de-
velopment characterized by bilateral near-contiguous ec-
topic neuronal nodules found along the lateral ventricles
[6, 7]. It may be isolated or associated with other brain
malformations, including hippocampal malformation
and cerebellar hypoplasia, bilateral fronto-perisylvian or
temporo-parietooccipital polymicrogyria, hydrocephalus
and microcephaly. In a smaller group of patients, PVNH
was found to be associated with non-neurologial defects
including Ehlers–Danlos syndrome, frontonasal dysplasia,
limb abnormalities, ambiguous genitalia and fragile-X syn-
drome. Finally, several distinct subgroups of patients have
been identified with an unusual PVNH presentation, in-
cluding a micronodular appearance, unilateral distribution
and laminar or ribbon-like shapes [23]. Progressive lung
involvement in FNLA-related PVNH has been reported in
a limited number of cases [2, 11–22] and emphysematous
lesions in the pulmonary parenchyma are the characteris-
tic findings of this mutation.
We report the case of a male infant with a novel
pathogenic variant of the FLNA gene mutation, who
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developed significant lung disease and in whom a peri-
ventricular nodular heterotopia was also diagnosed.
Case presentation
A 32 day old male infant was referred to our department,
from another hospital, with acute respiratory distress syn-
drome and suspected congenital pulmonary malforma-
tion. The baby (fourth child of nonconsanguineous
caucasian parents) was born by vaginal delivery at 37
weeks’ gestation, with a weight of 3140 g. The first month
of life was unremarkable. The family had no history of
genetic or metabolic diseases or congenital disorders.
At admission, the physical examination confirmed re-
spiratory distress, general hypotonia due to respiratory fail-
ure and fatigue, bilateral inguinal hernia and deformities of
the lower limbs (pes tortus congenitalis and hip dysplasia).
A chest X-ray (Fig. 1) and computed tomography (CT)
scan (Fig. 2, Panels a, b) showed severe hyperinflation of
the apical segment of the left lung and mediastinal shift to
the right. A presumptive diagnosis of congenital lobar em-
physema (CLE), including the lower lobe was made. After
the stabilization of the subject’s respiratory conditions (non
invasive respiratory support, fluid and electrolyte manage-
ment, broad spectrum antibiotics, bronchodilatator),
considering the inclusion of the superior lobe and the
upper part of the lower lobe we decided to proceed with
observation.
Two months later, the child’s condition deteriorated
with worsening in respiratory distress; the child was un-
able to maintain saturation even with oxygen support.
CT-angiography (Fig. 2, Panels c, d) was ordered and
revealed a severe lobar emphysema of the anterior to the
apicoposterior segment of the left upper lobe, with
displacement of mediastinal structures to the right and
compression of the right structures. A subsegmental
atelectasis and areas of air trapping in the apicoposterior
segment of the left lower lobe were also noted. Angiog-
raphy showed peripheral pulmonary vascular attenuation
and central pulmonary artery enlargement.
Surgery included a left upper lobectomy and segmen-
tal resection of the left lower lobe. The histopathology
report was consistent with a generalized lung growth ab-
normality with alveolar enlargement and simplification.
Following surgery, multiple attempts to extubate the in-
fant failed and he had a persistent oxygen requirement.
Chronic respiratory failure ensued with progressive worsen-
ing of the ventilatory performance, necessitating continuous
mechanical ventilation, with gradual support parameter
adjustments and tracheostomy at age 12months.
After prolonged multidisciplinary discussion, the decision
to perform a surgical thoracoscopic lung biopsy was made
in order to obtain additional data on the pathological pul-
monary features for prognostic predictions and therapeutic
decisions. Histopathology revealed alveolar enlargement,
perivascular and interstitial fibrosis and intra-alveolar
hemorrhages (Fig. 3).
Genetic testing was performed during the course of
clinical care, after obtaining informed consent. Next
generation sequencing on genomic DNA was performed
using the NimbleGen SeqCap Target Enrichment kit
(Roche) designed to capture several genes involved in
pulmonary surfactant protein deficiency and skeletal
abnormalities. A library was prepared following the
manufacturer’s instructions and subsequently sequenced
on an Illumina NextSeq550 instrument. Sequence data
were carefully analyzed and the presence of all suspected
Fig. 1 Chest X-ray at admission shows left pulmonary areas of hyperinflation (see arrows)
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variants were checked in the public databases (dbSNP,
1000 Genomes, and Exome Aggregation Consortium).
The identified variants were confirmed by Sanger
sequencing, following a standard protocol (BigDye® Ter-
minator v3.1 Cycle Sequencing Kit,Life Technologies).
No potentially causative variants were found in genes
associated with cystic fibrosis, pulmonary surfactant pro-
tein deficiency or mutations in the SETBP1 gene associ-
ated with Schinzel–Giedion syndrome (a rare autosomal
dominant disorder that results in facial dysmorphism
and organ and bone abnormalities).
Sequencing analysis showed a new mosaic frameshift
variant, NM_001456.3: c.7391_7403del, p.Val2464Alafs*5
in the FLNA gene that was not present in the maternal
blood DNA. This variant has not been previously reported
in individuals with FLNA-related disorders, but can be
classified as likely pathogenic (Class 4) according to the
ACMG guideline and it is expected to cause disease. It is
not present in any public databases, dbSNP (http://www.
ncbi.nlm.nih.gov/projects/SNP/, 1000 Genomes Project
(http://www.internationalgenome.org/), EVS (http://evs.gs.
washington.edu/EVS/), ExAC (http://exac.broadinstitute.
org/) and can be considered as a private variant.
The same mutation was identified in DNA from
salivary and pulmonary mesenchymal stem cells of
the patient [24].
Brain magnetic resonance imaging (MRI) depicted
PVNH (Fig. 4), although the patient was not suffering
from any neurological symptoms at this stage.
At 14months follow-up, the patient requires mechanical
ventilation and artificial nutrition to maintain his growth.
Epilepsy and other neurological manifestations were not
recorded.
Discussion and conclusions
Filamin A is an actin-linking protein that regulates cell
shape and migration of many cell types, including
neuronal, vascular and cutaneous cells [15]. Filamin A is
composed of three main functional domains: (1) a
tandem N-terminal calponin-homology domain (CHD1
and CHD2), which confers F-actin binding properties;
(2) 15 + 8 internally homologous Ig-like repeats sepa-
rated by a short run with an unique sequence (hinge 1),
important for flexibility; and (3) a second short run
(hinge 2) followed by the C-terminal repeat 24, which
are important for binding to a wide range of proteins
and for dimerization [25]. Null mutations in the FLNA
gene, lead to defects in neuronal migration, vascular
function and connective tissue integrity. In contrast,
gain-of-function missense mutations in this same gene
produce a spectrum of malformations in multiple organ
systems, especially the skeleton [26].
Fig. 2 CT thorax at admission (Panels a, b) and two months later (Panels c, d). The arrows indicate the hyperinflation area. Panels a, c: axial
position; Panel b, d: sagittal position
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Here, we report the case of a male child in whom a
new mosaic loss-of-function variant of the FLNA gene
c.7391_7403del; p.Val2464Alafs*5 was found by next
generation sequencing, resulting in significant lung
disease characterized by emphysematous lesions and
perivascular and interstitial fibrosis. The mutant allele
frequency of this variant is estimated to be around 36%
considering the numbers of sequence reads of the
mutant and the wildtype alleles. This 13 bp deletion is
predicted to result in a truncated protein that lacks the
hinge 2 domain and repeat 24 probably leading to a loss
of binding and dimerization ability that is essential for
the FLNA function.
This report confirms an association between a FLNA
gene mutation and lung disease. PNVH was observed and
limb deformities were also present. There are 25 previous
case reports in the literature on FLNA-related disorders
with the pulmonary phenotype (Table 1) [2, 9, 13–22].
Lung diseases are associated with documented PNVH in
84% of the reviewed cases. The presence of cardiac
co-morbidities, such as patent ductus arteriosis, valvular
disease and aortic root dilatation, have also been reported
[2–10, 13–15, 18]. Mutations in the filamin A gene are
inherited in an X-linked (Xq28) dominant manner, with
perinatal lethality in most males, whereas in female
patients the prognosis depends on the severity of the
Fig. 3 Histological features. In Panel a, areas in blue and the arrows indicate the perivascular and interstitial fibrosis and intra-alveolar
hemorrhages (Azan-Mallory coloration, magnification 10x). In Panel b, areas in brown (Tenascin, magnification 10x) indicate where Tenascin was
overexpressed, highlighting the extensive parenchymal fibrosis. TNC localization in the normal lung was un-detectable; TNC is specifically and
transiently expressed upon tissue injury and down-regulated when tissue repair or scarring is concluded [38]
Pelizzo et al. BMC Pediatrics           (2019) 19:86 Page 4 of 10
associated cardiovascular abnormalities [20]. Of the previ-
ously published cases 21/25 (80%) were female (Table 1).
Perinatal lethality occured in six of these reported cases
(24%; 5 females and 1 male); in all cases, cardiopathies
were also found [2–10, 13–15, 18]. As reported in Table 1,
a large spectrum of FLNA mutations are detected in pa-
tients with pulmonary disease, including missense muta-
tions [9, 13, 14, 19], nonsense mutations [2, 20], deletions
[13, 15, 16, 21], duplications [13, 14, 18, 21], truncating
mutations [17, 21], and frameshift mutations [14].
In these patients, the presentation of respiratory failure
occurred at a median age of 1 month (range, birth to 72
months). However, one reported patient developed pro-
gressive obstructive lung disease at the age of 38 years
[20]. The clinical presentation of lung involvement was
variable, ranging from multiple episodes of intercurrent
pulmonary infections [13], to progressive severe pulmon-
ary disease [13, 14, 16–18, 20]. A variable outcome and
management course were reported in the previously re-
ported cases. In a limited number of patients, supportive
therapy was successful [13, 16, 17, 19]. Surgical interven-
tion in the form of lobar resection [2, 9, 13], as in our case,
or lung transplantation, may be indicated in severe cases
where supportative therapies are not successful [14, 20].
The pulmonary growth abnormality associated with
FLNA deficiency consists of multilobar overinflation pre-
dominantly affecting the upper and lower lobes, with
coarse septal thickening and varying lower lobe atelectasis
with pruning of the peripheral pulmonary vasculature [27].
The role of FLNA in the development of lung disease is
still not well elucidated. Considering that during respir-
ation the lungs are subjected to mechanical forces and be-
cause FLNA plays important role in cell mechanosensing
and mechanotransduction, abnormal FLNA interactions
could affect pulmonary viscoelastic properties and disturb
alveolar formation and growth [14, 28]. However, a role in
T cell activation, interleukin production [29], inflammatory
signaling [30] and interaction with the cystic fibrosis trans-
membrane conductance regulator [31] has also been
proposed. Furthermore, the crucial role of FLNA action in
Fig. 4 Brain MRI. Appearance of nodules (indicated by arrows) in periventricular grey matter heterotopia (images b, e, d), surrounding the left
temporal horn and merging with the hippocampal cortex (image c). Supratentorial signal alterations with T2 and FLAIR hyperintense (images a,
indicated by triangles) as in demyelinating lesions
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mesenchymal migration, should not be excluded. Alter-
ations in mesenchymal properties could be directly related
to defects in cell migration during embryonic development
and in pulmonary damage described in FLNA-defective pa-
tients [32]. Further studies are needed to investigate the
functional role of tissue-resident lung mesenchymal stem
cells in health and disease. Considering the successful use
of stem cell therapy in the treatment of chronic progressive
pulmonary disease in adults [31–37], future perspective
stem cell treatment also in FLNA mutation-related lung
disorders in children should be investigated. In conclusion,
we report a novel mosaic loss-of-function variant of the
FLNA gene associated with a severe lung disorder and
PNVH. The lung disorder led to respiratory failure during
infancy and these pulmonary complications may be the
first sign of this disorder. Early recognition with thoracic
imaging is important to guide genetic testing, neuroimag-
ing and to define optimal timing of potential therapies,
such as lung transplant in progressive lung disease [14].
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